ABAX 55.00 Abaxis Inc $ABAX Hit a 52 week high of 55.10

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 10:04 AM

ABAX 55.00 Abaxis Inc $ABAX Hit a 52 week high of 55.10 Closing the day 09:45 at 55.00 -0.01 -0.02% With a day low of 54.58 and a total volume of 15,788.

ABAX Recent Posts: http://investorshangout.com/Abaxis-ABAX-53195/

ABAX Abaxis Inc Recent Headline News

Strength Seen in Cerus (CERS): Stock Gains 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 38 mins ago
Cerus (CERS) was a big mover last session, with shares rising nearly 6% on the day.
CERS: 4.32 (-0.10), ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34), OSUR: 8.96 (unch)

Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostic Forum
PR Newswire - 2 hrs 3 mins ago
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Don Wood, Chief Operating Officer, will present at the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum on Thursday, November 20, 2014 at 8:00 a.m. ET. The conference will be held at The Westin Grand Central Hotel in New York City.
ABAX: 55.18 (+0.17)

Allscripts Healthcare and CHI Sign Hosting Solution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:40PM CST
By utilizing Allscripts Healthcare Solutions, Inc. (MDRX) Hosting Solution, Catholic Health Initiatives expects improved system availability, reduced IT infrastructure expenditures as well as enhanced end user performance.
GWPH: 75.50 (-0.34), ABAX: 55.18 (+0.17), MDRX: 12.62 (+0.16), MRGE: 3.06 (-0.03)

3 Stocks Going Ex-Dividend Tomorrow: ERH, PHT, ABAX
at The Street - Wed Nov 12, 9:52AM CST
ERH PHT ABAX are going ex-dividend tomorrow, Thursday, November 13, 2014
PHT: 17.73 (-0.03), ERH: 13.28 (-0.07), ABAX: 55.18 (+0.17)

Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.43 (+0.02), VIVO: 16.39 (-0.05), ABAX: 55.18 (+0.17), OSUR: 8.96 (unch)

INSYS Therapeutics (INSY) in Focus: Stock Rises 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:44AM CST
INSYS Therapeutics, Inc. (INSY) was a big mover last session, as the company saw its shares surge 12%
ICUI: 85.26 (+0.31), INSY: 38.80 (+0.09), ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34)

Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34), OSUR: 8.96 (unch), OMER: 19.24 (-0.33)

Abaxis, Inc. to Present at the Stifel 2014 Healthcare Conference
PR Newswire - Wed Nov 12, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Don Wood, Chief Operating Officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 9:45 a.m. ET. The conference will be held at the New York Palace Hotel in New York City.
ABAX: 55.18 (+0.17)

Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), OMCL: 32.60 (+0.04)

Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:50PM CST
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), BCR: 164.63 (-0.96), ABAX: 55.18 (+0.17)

Ex-Dividend Reminder: Abaxis, Chemed and AmerisourceBergen
DividendChannel.com - Tue Nov 11, 9:50AM CST
Looking at the universe of stocks we cover at Dividend Channel, on 11/13/14, Abaxis, Inc. , Chemed Corp , and AmerisourceBergen Corp.
ABAX: 55.18 (+0.17)

Eagle Pharmaceuticals (EGRX) Jumps: Stock Gains 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:46AM CST
Eagle Pharmaceuticals (EGRX) was a big mover last session, with shares rising over 8% on the day.
ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34), EGRX: 12.65 (-0.15)

Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), WAG: 66.99 (+0.03)

Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 196.69 (+0.48), EBS: 24.15 (-0.17), ABAX: 55.18 (+0.17), ABBV: 63.26 (-0.37)

Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.39 (-0.05), ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34), OSUR: 8.96 (unch)

BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), BIOS: 5.79 (-0.07)

Allscripts Healthcare Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 12:30PM CST
Allscripts Healthcare Solutions, Inc. (MDRX) posted adjusted earnings of 2 cents per share in the third quarter of 2014 which missed the Zacks Consensus Estimate by 3 cents.
GWPH: 75.50 (-0.34), ABAX: 55.18 (+0.17), MDRX: 12.62 (+0.16), MRGE: 3.06 (-0.03)

Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), OMCL: 32.60 (+0.04)

SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 196.69 (+0.48), SRDX: 21.76 (+0.07), ABAX: 55.18 (+0.17), ABBV: 63.26 (-0.37)

Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.43 (+0.02), WMGI: 28.23 (-0.13), GWPH: 75.50 (-0.34), ABAX: 55.18 (+0.17)

Abaxis Inc. (ABAX) Stock Research Links

ABAX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Activewear Faces Class Action over Alleged Fraud

A Battle Over the Truth: Gildan's Legal Troubles Alright, buckle up, folks—it's time to dig deep into the gritty side of investing, where the glossy annual reports meet cold, hard skepticism. Gildan Activewear Inc., or GIL on the NYSE if you're still keeping track, has managed to embroil itself in some legal stews that even a seasoned trader like me can't ignore. Let's...

Labcorp Scoops Up BioReference Health For $722M+

Picture this: You’re a big fish like Labcorp ready to feast on smaller catches. That’s exactly what’s rolling out as OPKO Health cuts a deal to offload a chunk of its BioReference Health assets to Labcorp for a tidy $722 million in cash. Assets on the Move OPKO’s BioReference Health has long been a player in the clinical testing world, with a focus on services...

HYPOTHESIS Blends Style and Function in Health Gear

Pushing the Limits with HYPERX Knit Look, healthcare workers ain't just clocking in and out—they're on their feet all day, twisting, reaching, and moving. So when HYPOTHESIS tossed this shin-dig in Los Angeles for their HYPERX knit collection, it wasn't just to show off some snazzy scrubs. It was about bridging a gap: wellness meets grind. You reckon a pair of old...

Brewer Foundation Shatters Records with IPPF Entries

A New Milestone in Global Debate The Brewer Foundation is making waves across the debate world, claiming a groundbreaking enrollment for their 2026-27 International Public Policy Forum (IPPF). Let’s talk numbers for a moment—506 teams from a whopping 62 different countries, not to mention new entries from places like France, Mexico, Curaçao, and Russia, all eager to...

Strategic Moves in Biotech: The EQT-Qiagen Deal EQT Private Equity's latest maneuver has seasoned investors raising an eyebrow. They've just put an all-cash public takeover offer on the table for Qiagen, and no, this isn't your run-of-the-mill acquisition—it's a play steeped in strategy and capital dynamics. EQT's Portfolio Puzzle: Where Does Qiagen Fit? Let's break it...

Pearson Targets 2026 Growth with Strategic Moves

Pearson's Q3 Performance: Crunch Time Checking the rearview mirror at Pearson's nine-month journey into 2026, it's quite the sight. Q3 revved up with a 6% growth spurt, aligning neatly with market expectations. Ain't that a relief in today's rocky terrain of education and assessment? Holding a tight rein, they're on course to meet the mid-single digit revenue growth they...

Essity's Q3 2026: Profits Hold Firm Amid Challenges

Essity's Balance Act in Q3: A Close Examination No looking through rose-tinted glasses here—Essity navigated the third quarter of 2026 with mixed indicators. Despite the broad strokes of stability, there's plenty beneath the surface worth a seasoned investor's eye. The company's net sales inched up by 4.1% to SEK 36,060 million. A nice figure, sure, but if you peek...

Ben Felton to Lead AEIC as President for 2027

A New Face at the Helm of AEIC If you’ve been keeping tabs on the utility sector, then the recent shuffling of chairs over at the Association of Edison Illuminating Companies (AEIC) might have caught your eye. They just wrapped up their 142nd Annual Meeting in Ojai, where Ben Felton from Portland General Electric stepped into the limelight as the incoming President for...

Cognizant Buys DyFlex for SAP, AI Edge in ANZ

Why Cognizant's Move Matters Imagine being at the top of your game, only to realize you need more heavy-hitters to keep your edge. That’s this deal in a nutshell. Cognizant (NASDAQ: CTSH) is diving deep into AI-led enterprise transformation by scooping up DyFlex Solutions, a name with plenty of clout in the SAP ecosystem. What's Behind the DyFlex Acquisition? Founded in...

Annual Flu Shots May Save Lives: Accordia Health's Call

Flu Season Isn't Just Sniffles: Accordia Health Speaks Up Listen up folks, it’s that time again and no, it ain’t just about digging out last year's scarf. Flu season is rolling in faster than a train outta hell, and already folks are talking about flu cases creeping up during the summer sunshine. We got Dr. Cameron Kilpatrick over at Accordia Health ringing the bell...